For comprehensive long-term safety data, see our detailed long-term safety analysis
Normality of distribution was assessed using skewness and kurtosis statistics
Cat#76-0002 & Cat#76-0702) and STARTLE software module (PACKWIN-CSST, PACKWIN version 2.0
I had already disputed the first charge with my bank and now Ive had to dispute the second one too
In trials of the branded formulations, STEP 1 reported a -14.9% mean body-weight change with semaglutide at 68 weeks, and SURMOUNT-1 reported -20.9% with 15 mg tirzepatide at 72 weeks
Tirzepatide may be considered for adult patients who are obese (with a body mass index, or BMI, of 30 or greater) or overweight (BMI of 27 or higher) and have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol